文献速递外周动脉疾病

阿托伐他汀对外周动脉疾病患者氯吡格雷疗效的影响

Atorvastatin Effect on Clopidogrel Efficacy in Patients with Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2023-05-30

这项前瞻性观察研究纳入2020年12月至2022年8月接受血运重建的外周动脉疾病患者,比较单用氯吡格雷与联用氯吡格雷和阿托伐他汀者的血小板抑制情况。结果显示单用氯吡格雷组血小板抑制显著高于联用组(49.01% vs 34.54%,P=0.03),作者认为阿托伐他汀可能干扰氯吡格雷疗效。

要点

  • 单用氯吡格雷组血小板抑制显著高于氯吡格雷联用阿托伐他汀组(49.01% vs 34.54%,P=0.03)。
  • 阿司匹林单用与阿司匹林联用阿托伐他汀组间血小板抑制无统计学差异。
  • 作者认为服用阿托伐他汀者可能需要不含氯吡格雷的替代抗血小板方案。

核心结论

  • 氯吡格雷联用阿托伐他汀的患者血小板抑制显著低于单用氯吡格雷者,支持阿托伐他汀可能干扰氯吡格雷疗效的概念。
  • 作者认为服用阿托伐他汀的患者可能需要不含氯吡格雷的替代抗血小板方案以实现充分血栓预防。

研究设计与样本

  • 前瞻性观察研究,纳入2020年12月至2022年8月接受血运重建的患者,比较氯吡格雷联用阿托伐他汀组与单用氯吡格雷组。
  • 共入组182例患者,72例符合研究标准,对这72例的87份样本进行分析;单用氯吡格雷组31例(43.05%),联用阿托伐他汀组41例(56.94%)。
  • 围手术期至术后6个月系列行血栓弹力图血小板图(TEG-PM)分析,评估血小板抑制百分比,采用非配对t检验进行统计分析。

主要发现

  • 单用氯吡格雷组血小板抑制显著高于氯吡格雷联用阿托伐他汀组(49.01% vs 34.54%,P=0.03)。
  • 阿司匹林单用与阿司匹林联用阿托伐他汀组间血小板抑制无统计学差异。

临床怎么用

  • 作者认为服用阿托伐他汀的患者可能需要不含氯吡格雷的替代抗血小板方案以实现充分血栓预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both clopidogrel and atorvastatin metabolism are rooted in hepatic cytochrome p450 activation. There are published reports of atorvastatin interfering with clopidogrel metabolism by inhibiting the activation of clopidogrel. This in turn would decrease the therapeutic effect of clopidogrel potentially resulting in an increase in thrombotic events in patients who are taking both medications. The emergence of viscoelastic assays, such as Thromboelastography with platelet mapping (TEG-PM), has been utilized to identify prothrombotic states and may provide insight into a patient's microvascular coagulation profile. The aim of this prospective, observational study was to delineate the differences in platelet function between patients on clopidogrel alone versus those on clopidogrel and atorvastatin in patients that are undergoing peripheral revascularization. METHODS: All patients undergoing revascularization between December 2020 and August 2022 were prospectively evaluated. Patients on clopidogrel and atorvastatin were compared to those on clopidogrel alone. Serial perioperative TEG-PM analysis was performed up to 6 months postoperatively and the platelet function in terms of percent inhibition was evaluated in both groups. Statistical analysis was performed using unpaired t-test to identify differences in platelet function. RESULTS: Over the study period, a total of 182 patients were enrolled. Of this cohort 72 patients met study criteria. 87 samples from the 72 patients were analyzed. 31 (43.05%) patients were on clopidogrel alone and 41 (56.94%) were on clopidogrel and atorvastatin. Patients on clopidogrel alone showed significantly greater platelet inhibition compared to those on clopidogrel and atorvastatin [49.01% vs. 34.54%, P = 0.03]. There was no statistical difference in platelet inhibition between groups in terms of aspirin use alone versus aspirin and atorvastatin. CONCLUSIONS: Patients on clopidogrel and atorvastatin showed significantly less platelet inhibition compared to those on clopidogrel alone, supporting the concept that atorvastatin may interfere with the therapeutic effect of clopidogrel. Patients taking atorvastatin may require an alternative antiplatelet therapy regimen that does not include clopidogrel to achieve adequate thromboprophylaxis.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Suarez Ferreira SP, Hall RP, Majumdar M, et al. Atorvastatin Effect on Clopidogrel Efficacy in Patients with Peripheral Artery Disease. Ann Vasc Surg. 2023. PMID: 37257642. doi:10.1016/j.avsg.2023.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。